|Dr. Michel Detheux Ph.D.||Pres, CEO & Director||936.5k||N/A||1966|
|Mr. Matthew A. Call M.B.A.||Chief Operating Officer||626.98k||N/A||1973|
|Dr. Joanne Jenkins-Lager M.D.||Chief Medical Officer||669.5k||N/A||1972|
|Mr. Matthew Gall||Chief Financial Officer||N/A||N/A||1977|
|Dr. Yvonne McGrath Ph.D.||Chief Scientific Officer||N/A||N/A||1974|
|Mr. Ryan Baker||Head of Investor Relations||N/A||N/A||N/A|
|Mr. Phillipe Brantegem||Vice-Pres of HR||N/A||N/A||N/A|
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used to engage the Fc gamma receptor, or Fc?R to activate dendritic cells and macrophages and to promote antibody-dependent cellular cytotoxicity, or ADCC activity. Iteos Therapeutics, Inc. was founded in 2011 and is headquartered in Watertown, Massachusetts.
iTeos Therapeutics, Inc.’s ISS Governance QualityScore as of September 1, 2022 is 9. The pillar scores are Audit: 8; Board: 8; Shareholder Rights: 8; Compensation: 10.